Ascle Healthcare Group Signs MoU with MiRXES for GASTROClear Distribution
Ascle Healthcare Group is proud to announce the signing of a Memorandum of Understanding (MoU) with MiRXES Pte. Ltd. on 1 September 2022, formalising our partnership for the distribution of GASTROClear—a groundbreaking blood test for the early detection of gastric cancer.
Developed by MiRXES, a Singapore-headquartered biotechnology company, GASTROClear is the world’s first molecular blood test approved for detecting gastric cancer in individuals who may not yet show symptoms. This innovative screening solution is powered by RNA technology and represents a major step forward in the global fight against cancer.
Through this collaboration, Ascle reaffirms its commitment to advancing preventive healthcare and improving early detection efforts for at-risk communities.
Together with MiRXES, we strive to change lives—one test at a time.
For more information, please WhatsApp us or Contact Us.
